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Salmonella enterica strains are enteropathogenic bacteria that survive and proliferate within vacuolar com-
partments of epithelial and phagocytic cells. Recently, it has been reported that fibroblast cells are capable of
restricting S. enterica serovar Typhimurium intracellular growth. Here, we show that prolonged residence of
bacteria in the intracellular environment of fibroblasts results in the appearance of genetically stable small-
colony variants (SCV). A total of 103 SCV isolates, obtained from four independent infections, were subjected
to phenotypic analysis. The following phenotypes were observed: (i) -aminolevulinic acid auxotrophy; (ii)
requirement for acetate or succinate for growth in glucose minimal medium; (iii) auxotrophy for aromatic
amino acids; and (iv) reduced growth rate under aerobic conditions not linked to nutrient auxotrophy. The
exact mutations responsible for the SCV phenotype in three representative isolates were mapped in the lpd,
hemL, and aroD genes, which code for dihydrolipoamide dehydrogenase, glutamate-1-semyaldehyde amino-
transferase, and 3-dehydroquinate dehydratase, respectively. The lpd, hemL, and aroD mutants had intracel-
lular persistence rates in fibroblasts that were 3 to 4 logs higher than that of the parental strain and decreased
susceptibility to aminoglycoside antibiotics. All three of these SCV isolates were attenuated in the BALB/c
murine typhoid model. Complementation with lpd, hem, and aroD genes restored the levels of intracellular
persistence and antibiotic susceptibility to levels of the wild-type strain. However, virulence was not exhibited
by any of the complemented strains. Altogether, our data demonstrate that similar to what it has been reported
for SCV isolates of other pathogens, S. enterica SCV display enhanced intracellular persistence in eucaryotic
cells and are impaired in the ability to cause overt disease. In addition, they also suggest that S. enterica SCV
may be favored in vivo.
The species Salmonella enterica comprises a series of facul-
tative intracellular pathogens that cause gastroenteritis and
systemic infections in humans and animals (17, 38). Diverse
host-adapted S. enterica serovars are also capable of triggering
asymptomatic and persistent infections at relatively high rates
(12, 15). The major hallmarks of Salmonella pathogenesis in-
clude the capacity of the bacteria to invade nonphagocytic cells
and their capacity to survive within phagocytic cells. These two
virulence traits were inferred in initial studies involving infec-
tion of tissue culture cells (reviewed in references 18, 19, 20,
and 38). Subsequent work with epithelial cells and macro-
phages focused on characterization of the vacuolar compart-
ment in which the bacteria reside (2, 10, 21, 23, 25, 36, 42,
48–51, 53). The murine infection model has also been very
valuable for identification of other virulence functions, such as
those encoded in Salmonella pathogenicity island 2, which are
critical for intracellular survival and systemic disease (38).
Despite the relevance of the murine model, infection of
tissue culture cells has been very useful for determining differ-
ences in the intracellular lifestyles of S. enterica within distinct
host cell types (9). In most cases, massive intracellular bacterial
growth is observed regardless of the epithelial or macrophage
cell line that is used. The situation is different in macrophages
isolated from animals, which are capable of arresting bacterial
growth (11). Remarkably, in vivo studies have demonstrated
that S. enterica proliferates predominantly within liver and
spleen macrophages during systemic infection of mice (44, 47).
This finding indicates that in contrast to the information ob-
tained with the in vitro infection models, macrophages are the
preferred niche used by S. enterica to proliferate in vivo. In
recent reports workers have also described the capacity of S.
enterica to colonize other types of antigen-presenting cells,
such as dendritic cells. However, both in vitro and in vivo
studies have demonstrated that bacteria located within these
specialized cells do not exhibit massive intracellular growth
(22, 37).
Recent studies have shown that cultured melanocytes and
fibroblasts restrict intracellular proliferation of S. enterica (13,
32, 33). Upon infection of these cell types, either S. enterica
remains in a latent nongrowing stage (13, 33) or the mass
increases but the cell division process does not culminate (32).
The latter defect leads to formation of long filamentous bac-
teria within the infected cells (32, 33), a phenomenon also
recently observed in macrophages (46). Workers in our labo-
ratory have demonstrated that S. enterica serovar Typhimu-
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rium is able to attenuate intracellular growth upon infection of
fibroblasts. Thus, mutations that cause loss of function in vir-
ulence-related genes, such as phoP-phoQ, slyA, spvR, and rpoS,
result in exacerbated intracellular bacterial growth (13). This
observation indicates that there is delicate interaction between
the pathogen and the infected fibroblast, resulting in establish-
ment of a latent state of the bacteria within the host cell.
Recently, the role of fibroblasts in bacterial infections was
supported by a study that revealed the presence of Mycobac-
terium tuberculosis, a bacterium that remains in a latent state in
a high percentage of the human population, in this specific host
cell type (28). Interestingly, it has also been shown recently
that S. enterica serovar Pullorum persists intracellularly in vivo
within splenic chicken macrophages (60). Whether adaptation
to the intracellular persistence stage is accompanied by stable
changes in the physiology of S. enterica is not known.
It has been reported that Staphylococcus aureus variants that
display physiological changes, such as a low growth rate under
aerobic conditions, arise at a high frequency in the intracellular
environment of cultured endothelial cells (54). These variants,
known generically as small-colony variants (SCV), are fre-
quently isolated from cases of persistent and relapsing infec-
tion and have an enhanced capacity to persist intracellularly
when they are tested in tissue culture infection models (1, 30,
40, 56, 57). A phenotypic trait shared by most S. aureus SCV is
a defect in synthesis of either menadione or hemin (34, 58).
Lack of either of these two compounds likely alters the func-
tionality of the electron transport chain, leading to a reduced
growth rate under aerobic conditions and pleiotropic effects,
such as decreased alpha-toxin expression, decreased uptake of
aminoglycoside antibiotics, and increased expression of clump-
ing factor and fibronectin-binding proteins (52, 58). Different
authors have claimed that S. aureus SCV might be selected by
exposure to subinhibitory concentrations of antimicrobial
agents, although SCV have also been isolated after antibiotic-
free intervals (reviewed in reference 58). SCV linked to
chronic and recurrent infections have been described for other
pathogens, such as Escherichia coli, Pseudomonas aeruginosa,
and Burkholderia pseudomallei (26, 27, 45).
SCV isolates of S. enterica have not been characterized pre-
viously. However, salmonellae are pathogens that are prone to
trigger chronic and persistent infections (5, 62). Since this
pathogen adapts to establish a latent, nongrowing state in the
intracellular environment of fibroblasts (13, 33), we studied the
fate of intracellular bacteria within this specific cell type. Our
results suggest that, as observed for S. aureus, prolonged in-
tracellular residence of S. enterica serovar Typhimurium within
eucaryotic cells leads to selection of SCV.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The S. enterica serovar
Typhimurium strains and plasmids used in this study are listed in Table 1. The
genomic library of S. enterica serovar Typhimurium strain LT2/TN1379
(leuBCD485) was provided by G. C. Miller (Department of Microbiology, Uni-
versity of Illinois, Urbana). It was constructed in vector pBR328 by Sau3AI
partial digestion of chromosomal DNA and ligation of 8- to 12-kb fragments to
the BamHI-digested vector. The library was stored in P22 HT 105/1 int201 phage
(referred to below as P22 HT). Allele numbers for S. enterica SCV isolates
described in this study were obtained from the Salmonella Genetic Stock Center,
University of Calgary, Calgary, Alberta, Canada. All strains were grown in Luria-
Bertani (LB) medium supplemented with ampicillin (50 g ml1) or kanamycin
(50 g ml1) when appropriate.
Mapping of mutations linked to the SCV phenotype. The following two map-
ping strategies were used to identify the mutations present in SCV isolates: (i)
Tn10dTet mutagenesis and detection of insertions linked to the small-colony
phenotype upon P22 HT transduction; and (ii) complementation with a pBR328-
derived library of serovar Typhimurium strain LT2. Tn10dTet mutagenesis was
performed by transducing an F-borne Tn10dTet insertion into an LT2 derivative
carrying pNK2880, a plasmid that harbors a gene encoding the altered target
specificity (ATS) transposase (31). Individual Tn10-carrying isolates were then
pooled and lysed with P22 HT. The lysate was used to select Tn10dTet insertions
TABLE 1. S. enterica serovar Typhimurium strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s) Source or reference
Strains
SL1344 hisG rpsL, mouse virulent 29
SV4042 SL1344 hemL-801 This study (SCV isolate)
SV4043 SL1344 lpd-201 This study (SCV isolate)
SV4175 SL1344 aroD This study (SCV isolate)
SV4139 SV4042(hemL-801)/pIZ919(hemL) This study
SV4137 SV4043(lpd-201)/pIZ918(lpd) This study
SV4601 SV4175(aroD)/pIZ961(aroD) This study
SV4384 SL1344 aroA551::Tn10 This study
Plasmids
pBR328 Cloning vector, Tetr Ampr Used for construction of S. enterica serovar Typhimurium LT2 chromosomal
DNA library
pBluescript II SK() Cloning vector, lac, Ampr Stratagene
PNK2880 Ampr 31
PIZ916 pBR328, hemL Library clone that complemented SCV phenotype in SV4042 (hemL)
pIZ917 pBR328, hemL Religation of 6.5-kb SalI fragment from pIZ916
pIZ919 pBluescript II, hemL NheI-SalI fragment from pIZ917 cloned in pBluescript II SK()
pIZ912 pBR328, lpd Library clone that complemented SCV phenotype in SV4043 (lpd)
pIZ913 pBR328, lpd Religation of 8.5-kb HindIII fragment from pIZ912
pIZ915 pBR328, lpd Religation of 6.0-kb AvaI fragment from pIZ913
PIZ918 pBluescript II, lpd HindIII-AvaI fragment from pIZ915, converted in blunt fragment (AvaI site)
and cloned in HindIII-SmaI sites of pBluescript II SK()
pIZ956 pBR328, aroD Library clone that complemented SCV phenotype in SV4175 (aroD)
PIZ961 pBluescript II, aroD 5.5-kb EcoRV fragment from pIZ956 cloned in pBluescript II SK()
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that changed the SCV phenotype to the normal-colony-size phenotype. The
insertions were mapped by using the locked-in Mud-P22 prophage procedure
(7). The insertions linked to the SCV phenotype were also used to clone the
corresponding mutant alleles and to identify the exact mutation responsible for
the slow growth on plates. For complementation analysis, the pBR328-derived
library of strain LT2 stored in P22 HT was used to transduce an SCV isolate.
Plasmid DNA from normal-size colonies was purified and used to verify the
complementation results. The inserts present in the complementing plasmid
were subcloned by standard genetic procedures to determine the minimal insert
size that complemented the SCV phenotype. At this stage, the flanking regions
of the insert were sequenced with primers designed to amplify from vector
regions, and the gene(s) present was identified.
Bacterial infection of fibroblast cells. Infection of NRK-49F fibroblasts
(ATCC CRL1570) with S. enterica serovar Typhimuirum has been described
elsewhere (13). Briefly, fibroblasts were grown in Dulbecco modified Eagle
medium containing 5% fetal calf serum to 30% confluence at the time of
infection. Bacteria were grown overnight in LB medium at 37°C under static
conditions without shaking. The multiplicity of infection was 10 bacteria per
fibroblast cell, and the infection time was 20 min. Infected cells were washed
three times with phosphate-buffered saline (PBS) (pH 7.4) and incubated in fresh
tissue culture medium containing 100 g of gentamicin per ml. The antibiotic
concentration was decreased to 10 g ml1 at 2 h postinfection. At different
times postinfection, infected fibroblasts were lysed in 1% Triton X-100 for 5 min,
and the number of intracellular viable bacteria was determined by plating serial
dilutions of the cell extract onto LB agar plates. To avoid side effects of cell
culture saturation in the long-term infection experiments, the infected fibroblasts
were detached with a trypsin-EDTA solution at 48 to 72 h postinfection. The
entire cell population was transferred to larger culture dishes containing fresh
Dulbecco modified Eagle medium supplemented with 5% fetal calf serum and
gentamicin (10 g ml1). Caution was taken to avoid more than 80% confluence
at any time postinfection. Cytotoxicity in the infected cell cultures was negligible
at all times postinfection, as indicated by the absence of fibroblasts in the cultures
permeable to 1% propidium iodine. The possibility that bacteria were present in
the extracellular medium was examined by direct plating of tissue culture super-
natants. This control consistently showed that the number of viable extracellular
bacteria was very low at any time postinfection (0.1% of the number of viable
intracellular bacteria). The low number of viable extracellular bacteria was con-
sidered irrelevant since three washes with PBS were performed before Triton
X-100-mediated cell lysis.
Phenotypic analysis of SCV isolates. Phenotypic characterization of SCV
isolates was performed by using noncitrate E (NCE) medium (8). Carbon
sources, including glucose, glycerol, acetate, and succinate, were used at a con-
centration of 0.2% (wt/vol). -Aminolevulinic acid (ALA) (50 g ml1) was used
to test whether there was a deficiency in heme group synthesis. To test whether
there was auxotrophy for aromatic compounds, a mixture containing 30 mM
phenyalanine, 10 mM tryptophan, 10 mM tyrosine, 20 mM para-aminobenzoate,
and 20 mM dihydroxinbenzoate was used.
Antibiotic susceptibility assays. The MIC was determined by the E test (AB
Biodisk, Solna, Sweden) (61) by following the manufacturer’s instructions.
Virulence assays in BALB/c mice. Bacteria were grown overnight in LB me-
dium at 37°C under static conditions without shaking, centrifuged at 10,000  g
for 15 min, washed twice with sterile PBS (pH 7.4), and finally suspended in the
same buffer. Serial dilutions were used to infect orally (25 l) or intraperitoneally
(200 l) groups of five BALB/c female mice that were 7 to 8 weeks old. For the
oral challenges the bacterium-containing suspension was mixed with an equal
volume of 2.5% sodium bicarbonate–0.2% lactose to buffer the acidic pH of the
stomach. Survival of the mice was recorded for up to 3 weeks postinfection, and
50% lethal doses were calculated by the method of Reed and Muench (43).
Nucleotide sequence accession numbers. The sequences of the hemL and lpd
genes of S. enterica serovar Typhimurium strain SL1344 have been deposited
in the EMBL database under accession numbers AJ278741/SEN278741 and
AJ297525/SEN297525, respectively. Strain SV4042 (hemL) has an A-to-C point
mutation at position 889 of the hemL nucleotide sequence, which results in a
change from Pro to Thr. Strain SV4053 (lpd) has a G-to-A point mutation at
position 1084 of the lpd nucleotide sequence that results in a change from Gly to
Asp.
RESULTS
Selection of SCV of S. enterica serovar Typhimurium in
cultured fibroblasts. The fate of serovar Typhimurium virulent
strain SL1344 in NRK-49F fibroblasts, a cell line that restricts
intracellular bacterial growth (13), was investigated. Cells were
infected for 20 min, and the progress of the infection was
monitored for 6 days. Under these experimental conditions,
the viability of the intracellular bacteria decreased about 5 log
units by day 6 (Fig. 1A). The main decrease in viability was
observed 3 to 6 days postinfection. Consistent with previous
reports (13, 33), no phase of active bacterial growth was ob-
served at any time postinfection (Fig. 1A). A reproducible
phenomenon that occurred in these long-term infection assays
was the appearance of SCV when the cellular extract prepared
after 6 days was plated onto LB agar plates. SCV did not
appear in the population of intracellular bacteria at previous
times postinfection (data not shown). The proportion of SCV
in the intracellular population ranged from 45 to 100% in four
independent long-term infection experiments (Fig. 1B). These
results provided evidence that long-term persistence of S. en-
terica serovar Typhimurium within fibroblasts favors the selec-
tion of SCV isolates. Similar to what has been described for
other pathogens, such as S. aureus and E. coli (4, 45, 54, 57),
FIG. 1. Persistence of S. enterica serovar Typhimurium in fibroblasts favors selection of SCV isolates. (A) NRK-49F fibroblasts were infected
with serovar Typhimurium strain SL1344 for 20 min. The numbers of viable intracellular bacteria surviving gentamicin treatment were determined
at different times postinfection. The data are expressed relative to the number of viable bacteria quantified at 2 h postinfection. The values are
medians (and standard deviations) for a representative experiment with a total of six repetitions. (B) Numbers of normal-colony-size and SCV
isolates obtained in four different experiments at 6 days postinfection.
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the S. enterica SCV may have acquired specific mutations that
promote intracellular persistence within eucaryotic cells.
Phenotypic analysis of S. enterica SCV obtained from NRK-
49F fibroblasts. To gain insight into the nature of the muta-
tions responsible for the SCV phenotype, 103 SCV isolates
obtained from the four independent fibroblast infection exper-
iments (Fig. 1B) were screened for phenotypes described for
SCV of other pathogens that have been isolated (34, 58).
These phenotypes included auxotrophy for compounds in the
heme biosynthetic pathway and differential growth on NCE
minimal medium supplemented with intermediates of the
Krebs cycle as alternative carbon sources. Auxotrophy for ar-
omatic amino acids was also tested since it is known that aro
mutants grow more slowly than the wild type in LB medium,
which is limiting for these compounds. SCV isolates belonging
to each of these three phenotypic groups were identified (Ta-
ble 2). In addition, four SCV isolates grew in NCE minimal
medium containing glycerol and therefore were considered
prototrophs. Interestingly, a single SCV phenotypic class was
observed in most, if not all, the SCV isolates obtained from the
same experiment (Table 2). The phenotypic homogeneity in
the SCV populations is consistent with strong selection for the
SCV phenotype (about one SCV-linked mutation per intracel-
lular bacterial population consisting of 104 CFU). Because of
the small size of the sample, the probability of selecting two
different types of SCV mutations in the same experiment could
be expected to be extremely low. Finally, we observed that all
103 SCV isolates examined in this screening analysis behaved
like stable variants, with a rate of reversion to normal colony
size of 106 to 107, which is in the range of spontaneous
mutation frequencies. Altogether, our data indicate that there
are a variety of mutations that can cause the SCV phenotype in
S. enterica. Some of the phenotypes found closely correspond
to what has been found in S. aureus, such as a deficiency in
synthesis of the heme group (4). Our study revealed that other
types of mutations promote selection of S. enterica SCV in
fibroblasts, including mutations that cause either a defect in
providing catabolic compounds to the Krebs cycle or a reduced
growth rate due to nutrient auxotrophy (aro type mutations).
Genetic characterization of S. enterica SCV isolates selected
in cultured fibroblasts. Three SCV isolates collected in inde-
pendent experiments (experiments 1, 2, and 4 [Table 2]) were
designated strains SV4042, SV4053, and SV4175, propagated,
and subjected to a genetic analysis to identify the spontaneous
mutation responsible for the SCV phenotype. Unless indicated
otherwise, the strategy involved (i) Tn10dTet mutagenesis and
detection of insertions linked to the SCV phenotype upon P22
HT transduction; (ii) mapping of the insertion with the locked-
in Mud-P22 prophage procedure (7); and (iii) complementa-
tion with a pBR328-derived library of serovar Typhimurium
strain LT2.
After Tn10dTet mutagenesis in SV4042 and further trans-
duction, an insertion mapping between centisomes 3 and 4,
zaf-6309::Tn10dTet, was selected as an element that exhibited
30% linkage to the SCV phenotype. Complementation analysis
with the LT2 genomic library and subsequent subcloning pro-
vided a 2-kb fragment that restored normal colony size (plas-
mid pIZ919 [Table 1]). Sequencing of this insert revealed the
presence of a single open reading frame corresponding to the
hemL gene, which encodes glutamate-1-semialdehyde amino-
transferase. This enzyme catalyzes the last step in the biosyn-
thetic pathway of ALA, a precursor of the heme group (16).
Cloning and complete sequencing of the hemL allele harbored
by SV4042 showed that there was a point mutation that caused
a nonconservative amino acid change. Normal size colony was
obtained upon complementation with a hemL wild-type gene,
confirming that no additional mutation responsible for the
SCV phenotype was present in SV4042. The SCV-linked in-
sertion obtained in SV4053 after transposon mutagenesis,
zad-6310::Tn10dTet, was mapped at centisome 3, between the
nadC and proA loci. Complementation of normal colony size
and subcloning yielded a minimal 2.5-kb insert (plasmid
pIZ918 [Table 1]), which harbored a fragment of the aceF gene
and the complete lpd gene encoding lipoamide dehydrogenase
or the E3 component of pyruvate and 2-oxoglutarate dehydro-
genases (41). The Lpd protein has also been shown to be the L
component of the enzymatic complex known as the glycine
cleavage system (41). As in SV4042, cloning and sequencing of
the lpd allele harbored by the SV4053 isolate showed that there
was a point mutation that caused a nonconservative amino acid
change. Complementation analysis with an lpd gene restored
wild-type colony size, eliminating the possibility that there
were additional mutations in SV4053 responsible for the SCV
phenotype.
Genetic analysis of SV4175 was simpler since this SCV iso-
late was a representative of the Aro phenotypic class (Table
2, experiment 4). Complementation of the auxotrophy with the
LT2 plasmid library, followed by subcloning, revealed that
there was a minimal 5.5-kb insert that restored both prototro-
phy and large colony size (plasmid pIZ961 [Table 1]). Sequenc-
ing of an insert boundary revealed the presence of an open
reading frame homologous to ydiF, an E. coli gene whose
function is not known. In both E. coli and S. enterica, ydiF lies
near the aroD gene, which in turn is 14 kb away from aroH.
Since the insert that restored normal colony size was only 5.5
kb long, we concluded that the mutation carried by the SV4175
SCV isolate mapped in aroD, the gene that encodes 3-dehyd-
roquinate dehydratase. This enzyme is involved in the biosyn-
thesis of chorismate, a common precursor of aromatic amino
acids (35).
S. enterica serovar Typhimurium SCV show increased intra-
cellular persistence within fibroblasts. It has been shown
that S. aureus SCV display increased intracellular persistence
within cultured eucaryotic cells (4, 57). To assess whether the
S. enterica SCV selected in our study behaved in a similar
TABLE 2. Phenotypes of S. enterica serovar Typhimurium SCV





No. of isolates in the following phenotypic














1 13 0 13 0 0
2 60 57 0 0 3
3 12 11 0 0 1
4 18 0 0 18 0
Total 103 68 13 18 4
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manner, isolates SV4042 (hemL), SV4053 (lpd), and SV4175
(aroD) were used individually to infect NRK-49F fibroblasts.
All three SCV isolates exhibited intracellular persistence rates
higher than the intracellular persistence rate of the wild type
(Fig. 2A). The differences in intracellular viability between the
wild type and the SCV isolates increased progressively after 3
days postinfection (Fig. 2A). On day 6, both the hemL and
aroD mutants exhibited a viability rate that was close to 5 log
units higher than that of the wild type, whereas the viability
rate of the lpd mutant was about 4 log units higher (Fig. 2A).
None of the mutants overgrew the gentamicin-containing ex-
tracellular medium since direct plating on this medium yielded
low numbers of bacteria (0.1% of the viable intracellular
bacteria) at all times postinfection. In addition, the differences
in the intracellular persistence rates exhibited by the SCV
isolates selected in fibroblasts were reproduced with SCV
strains reconstructed with the SCV-linked Tn10dTet insertions
and SCV strains carrying knocked-out hemL, lpd, or aroD
alleles (data not shown). Complementation of the point mu-
tations selected in fibroblasts with hemL, lpd, and aroD
genes resulted in decreased intracellular persistence rates that
were even lower than the rate of the wild-type strain (Fig. 2B
to D). Altogether, these data confirmed that there was clear-
cut linkage between the SCV phenotype and an enhanced
capacity of S. enterica serovar Typhimurium to persist within
fibroblast cells.
Antibiotic susceptibility analysis of the S. enterica serovar
Typhimurium SCV isolates. SCV isolates of S. aureus, P. aeru-
ginosa, and E. coli have been shown to share defects in the
electron transport respiratory chain, which explains the low
growth rates of these variants under aerobic conditions (4, 45,
57). It has been proposed that these defects in the respiratory
chain reduce the membrane potential and impair energy-de-
pendent processes, such as transport of molecules across the
membrane. Uptake of antibiotics such as aminoglycosides,
which are dependent on a normal energized state of the mem-
brane, is notably reduced. Accordingly, some workers have
reported diminished aminoglycoside susceptibility of SCV of S.
aureus and P. aeruginosa recovered from cystic fibrosis patients
(27, 30, 58). To determine whether the S. enterica serovar
Typhimurium SCV isolates behave in a similar manner, their
susceptibilities to distinct classes of antibiotics, including -lac-
tam antibiotics, aminoglycosides, quinonoles, chlorampheni-
col, and trimethoprim-sulfamethoxazole, were examined. The
MICs of gentamicin and amikacin for the SCV isolates were
increased and were approximately 10-fold higher for the hemL
FIG. 2. Intracellular persistence of representative S. enterica serovar Typhimurium SCV isolates. (A) NRK-49F fibroblasts were infected with
wild-type strain SL1344 (E) and the SCV derivatives SV5053 (lpd) (), SV4042 (hemL) (‚), and SV4175 (aroD) ({). The numbers of viable
intracellular bacteria were calculated for different times postinfection and are expressed relative to the value obtained at 2 h postinfection. (B to
D) Behavior of the SV4137 (lpd/lpd), SV4139 (hemL/hemL), and SV4601 (aroD/aroD) complemented strains (■) compared to the behavior
of the SL1344 wild-type strain (E) and the corresponding SCV isolates (). Note that complementation with the wild-type genes caused a marked
decrease in the intracellular persistence.

















Amoxicillin-clavulanic acid 0.75 0.38 0.38 0.75 NAa NA NA
Cefotaxime 0.064 0.032 0.032 0.064 NA NA NA
Amikacin 1.5 16 3 3 1 1 1
Gentamicin 0.75 8 3 1.5 0.75 0.75 0.75
Nalidixic acid 6 1.5 4 2 3 3 4
Ofloxacin 0.094 0.094 0.094 0.094 0.094 0.047 0.064
Chloramphenicol 1.5 1 0.75 2 1 1 1.5
Trimethoprim-sulfamethoxazole 0.125 0.125 0.125 0.125 0.125 0.125 0.125
a NA, not applicable since the strain harbors the corresponding complementing gene cloned in the pBluescript II SK() plasmid, which carries an ampicillin
resistance determinant (Table 1).
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mutant (Table 3). A fourfold increase in the MIC of gentami-
cin was also noted for the lpd mutant (Table 3). No major
differences were observed between the wild type and the SCV
in terms of susceptibility to -lactam antibiotics, chloramphen-
icol, trimethoprim-sulfamethoxazole, and the quinonoles nali-
dixic acid and ofloxacin (Table 3). These results suggest that S.
enterica SCV isolates are less sensitive to aminoglycosides, an
expected finding considering that their mutations may poten-
tially lead to defects in respiratory metabolism. Complemen-
tation of the hemL, lpd, and aroD mutants with the corre-
sponding wild-type genes increased antibiotic susceptibility
(Table 3), confirming that there is a direct relationship be-
tween the point mutations responsible for the SCV phenotype
and the observed changes in sensitivity to aminoglycoside an-
tibiotics.
S. enterica serovar Typhimurium SCV isolates are attenu-
ated in the BALB/c mouse virulence model. Previous reports
provided evidence that there is reduced production of viru-
lence factors in SCV. For instance, S. aureus SCV isolates have
decreased alpha-toxin production and low coagulase activity
(58, 59), which may prevent overt disease and host cell damage.
Likewise, SCV of P. aeruginosa have been shown to be less
virulent in normal and moderately leukopenic mice (24). The
hemL, lpd, and aroD S. enterica SCV isolates showed marked
attenuation in BALB/c mice when they were tested by using
the oral or intraperitoneal route (Table 4). The data strongly
suggest that conversion of S. enterica to SCV notably reduces
the capacity of this pathogen to cause disease. Interestingly, no
apparent reversion to a virulent, normal-colony-size form was
observed in the animals since bacteria isolated from organs
retained the SCV phenotype on plates (data not shown). We
also tested whether complementation of the SCV phenotype
with the wild-type hemL, lpd, and aroD genes could result
in the reappearance of virulence. Among the complemented
strains, only the lpd/lpd strain displayed a slighter lower me-
dian lethal dose, although the lethal dose was only on the order
of 1 log lower than the lethal dose for the lpd SCV mutant
(data not shown). In contrast, both the hemL/hemL and
aroD/aroD strains remained as attenuated as the parental
SCV isolates. The latter results led us to examine whether the
complementing plasmid was unstable in vivo. Liver and spleen
extracts were prepared from mice that survived after 20 days of
bacterial challenge with the hemL/hemL and aroD/aroD
strains. Interestingly, SCV appeared in some cases, whereas
plasmid-bearing bacteria were not detected in any organ ex-
tract at this time postinfection (data not shown). These results
were consistent with rapid loss of the complementing plasmid
during infection.
DISCUSSION
To our knowledge, this study is the first one in which S.
enterica serotype Typhimurium SCV were isolated and char-
acterized. Phenotypic screening performed with 103 S. enterica
SCV isolates showed that at least some of them resemble SCV
of other bacterial pathogens, such as S. aureus. Thus, S. enterica
SCV isolates with mutations in genes related to respiratory
metabolism were identified. Examples include mutants requir-
ing ALA and mutants requiring intermediates of the Krebs
cycle for normal growth (hem and lpd phenotypic groups, re-
spectively). Interestingly, a defect in the hemB gene was the
first characterized mutation leading to an S. aureus SCV phe-
notype (57). A third phenotypic class, auxotrophy for aromatic
compounds, was also observed. Strikingly, most if not all SCV
isolated from each of the long-term fibroblast infections be-
longed to the same phenotypic group. This result was in accord
with the relatively low number of intracellular bacteria that
were analyzed. In fact, the size of the sample of viable intra-
cellular bacteria recovered from fibroblasts was on the order of
103 to 104cells. Despite this relatively low number of bacteria,
we successfully detected at least one mutation linked to the
SCV phenotype in each experiment. A detailed genetic anal-
ysis of each of the SCV isolates recovered from a single exper-
iment should provide clues about whether the isolates are
derivatives of a single clone. Regardless of whether all mutants
of a phenotypic class bear the same mutation, our results
demonstrate that the frequency of formation of S. enterica SCV
in fibroblasts is on the order of 103 to 104, in close agree-
ment with the study of Vesga et al., in which these authors
estimated that the rate of formation of S. aureus SCV in cul-
tured endothelial cells was 103 (54). However, one difference
between the two pathogens is that emergence of S. aureus SCV
in endothelial cells occurs after 72 h of infection, whereas S.
enterica SCV are selected in cultured fibroblasts after 6 days of
infection. The reasons for this difference are not known, but
factors such as the host cell type and/or bacterial type may
certainly contribute to it.
An interesting aspect of our study is the diversity of the
mutations that apparently account for an increased capacity of
S. enterica to persist intracellularly within fibroblasts. In the
hem and lpd mutants the respiratory metabolism capacity may
have been altered, probably leading to decreased generation of
oxygen-reactive subproducts. In this sense, S. enterica SCV
isolates would be less prone to self-intoxication in the intra-
vacuolar environment with these oxygen-derived compounds.
Further analysis of the cytochrome content and measurement
of the respiratory rates of these mutants should certainly pro-
vide new clues concerning this hypothesis. Our study also
showed that mutations that cause a defect in synthesis of aro-
matic amino acids, as in the case of aroD, favor intracellular
bacterial persistence in fibroblasts. Precedents for linkage be-
tween aro mutations and S. enterica persistence exist for aroA
purA double mutants, which persist for many months in organs
of BALB/c mice (62). We observed that infection of fibroblasts
with a well-characterized S. enterica aroA mutant resulted in an
intracellular persistence rate comparable to that of the aroD
TABLE 4. Virulence attributes of representative S. enterica serovar




SL1344 (wild type) 6  104 10
SV4042 (hemL) 4  107 1.5  103
SV4053 (lpd) 	5  109 	104
SV4175 (aroD) 	5.5  108 	1.1  105
a Median lethal doses were calculated by the method of Reed and Muench
(43).
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mutant (data not shown). Interestingly, both aroA and aroD
mutants are defective for synthesis of chorismate, a precursor
of not only aromatic amino acids but also folic acid, ubiqui-
none, and enterobactin. Lack of enterobactin might result in
iron starvation and subsequent impairment of cytochrome syn-
thesis. The fact that all SCV isolates selected in our study are
potentially defective in respiratory metabolism led us to pos-
tulate that switching to nonrespiratory metabolism may be a
major mechanism used by S. enterica to increase intracellular
persistence within eucaryotic cells.
The analysis of antibiotic sensitivity showed that, as reported
previously for SCV isolates of S. aureus and P. aeruginosa (3, 4,
34, 39, 45, 57, 58), the S. enterica SCV isolates have reduced
aminoglycoside sensitivity. This phenotype could indicate that
selection of S. enterica SCV within cultured fibroblast cells was
merely caused by prolonged exposure of intracellular bacteria
to gentamicin, an antibiotic maintained in the tissue culture
medium. Several observations argue against this possibility.
First, selection of S. aureus SCV by exposure to sublethal
concentrations of gentamicin has been reported to take place
in as little as 30 min (34). In contrast, recovery of S. enterica
SCV isolates from infected fibroblasts occurs at an appreciable
frequency only at very late infection times (6 days postinfec-
tion). Second, acquisition of gentamicin resistance concomi-
tant with the SCV phenotype seems to be a reversible phe-
nomenon in S. aureus since antibiotic-resistant SCV revert
rapidly to sensitive forms upon incubation in antibiotic-free
media (34). High-frequency reversion to normal colony size
and antibiotic-sensitive forms was not observed in any of the
S. enterica SCV isolates described in this study, which suggests
that there may be intrinsic differences between SCV selection
under antibiotic exposure conditions and intracellular persis-
tence within fibroblast cells. Third, the differences in the re-
versibility of the phenotype are accompanied by distinct levels
of antibiotic resistance. Whereas the MICs of gentamicin for S.
enterica SCV are 2- to 10-fold higher than those for the wild
type (Table 3), the MICs for S. aureus SCV are 20-fold
higher that those for the parental strain (34). Fourth, despite
the increased MICs of gentamicin for the three S. enterica SCV
isolates analyzed (1.5, 3, and 8 g ml1 for the aroD, lpd, and
hemL mutants, respectively [Table 3]), none of these variants
overgrew the tissue culture medium containing 10 g of
gentamicin per ml during the fibroblast infection experiment.
Finally, it has been demonstrated previously by using a quan-
titative enzyme-linked immunosorbent assay that unlike pha-
gocytic cells, NRK-49F fibroblasts do not accumulate gentami-
cin intracellularly (33). Altogether, these findings led us to
consider selection of S. enterica SCV isolates in the intracellu-
lar environment of fibroblasts a unique event unrelated to the
eventual exposure of intracellular bacteria to gentamicin.
Aside from the same behavior in terms of persistence within
fibroblasts cells and antibiotic susceptibility, the three S. en-
terica SCV clones characterized at a genetic level (hemL, lpd,
and aroD) were highly attenuated in the BALB/c mouse ty-
phoid model. S. enterica aroA mutants, which persist efficiently
in NRK-49F fibroblasts, were the first genetically defined
strains in which marked attenuation was observed in the mouse
model (29). In a subsequent study the workers also reported
attenuation of a hemA mutant of serovar Typhimurium (6),
which, in agreement with the results of the present study,
reinforces the contribution of the biosynthetic pathway in-
volved in synthesis of the heme group to S. enterica pathogen-
esis. We found evidence that when administrated by the oral
route, the hemL, lpd, and aroD SCV isolates are capable of
reaching the liver and spleen (data not shown). These results
are consistent with normal passage through the intestinal ep-
ithelium and subsequent failure of the bacteria to survive or
proliferate within phagocytic cells present in target organs.
Additional work is required to assess whether these SCV iso-
lates also persist intracellularly in vivo. Globally, our data are
consistent with previous observations made with S. aureus and
P. aeruginosa that show that there is direct linkage between the
SCV phenotype and an inability to cause overt disease (24, 57,
58). Interestingly, we did not find evidence of conversion to the
normal-colony-size type during infection with SCV isolates.
Furthermore, our attempts to complement the attenuation
phenotype displayed by the S. enterica SCV isolates with plas-
mids carrying the wild-type genes hemL, lpd, and aroD
were unsuccessful. The fact that the complementing plasmid
was lost rapidly during infection may explain these results. In
addition, plasmid-bearing bacteria are impaired in terms of the
ability to survive intracellularly (Fig. 2), which suggests that the
complemented bacteria may be rapidly counterselected in vivo.
Overall, these results confirm that there is a strict relationship
between the SCV phenotype and virulence attenuation in S.
enterica and selection occurring against normal-colony-size
phenotype once the bacteria have switched to an SCV.
A final consideration in our work was the possibility that
similar to S. aureus, natural SCV of S. enterica could be re-
sponsible for triggering chronic and persistent infections. So
far, virtually nothing is known about the mechanisms of
S. enterica persistence. However, as previously noted, an S.
enterica serovar Typhimurium aroA purA double mutant, which
is an SCV, persists in BALB/c mice (62). Although the basis of
this phenomenon has not been defined, it supports the hypoth-
esis that there is probably linkage between the SCV phenotype
and the in vivo persistence of S. enterica. This hypothesis does
not contradict the results of epidemiological studies showing
that bacteria released into the environment by asymptomatic
human and animal carriers retain pathogenic potential. Thus,
normal-colony-size bacteria may coexist in vivo with SCV, as
has been observed in long-term infection of fibroblasts (Table
2, experiments 1, 2, and 4). Under these conditions, an effective
host immune response elicited by the SCV (e.g., by an aro
mutant [29]) may limit the ability of normal-colony-size bacte-
ria to cause disease. Reactivation of disease due to non-SCV
bacteria would occur only during periods when immunity is
reduced. Alternatively, reactivation of the disease may be as-
sociated with the appearance of second mutations that sup-
press the SCV phenotype. Such a concept has been postulated
for the reactivation of infection in the case of chronic infec-
tions caused by an E. coli hemB mutant (45). Finally, it should
be noted that in the specific case of serovar Typhi, a host-
adapted serovar that triggers chronic and asymptomatic infec-
tions in humans, many clinical isolates are auxotrophs for
aromatic amino acids (55). Altogether, these observations in-
dicate that a more profound molecular analysis of S. enterica
SCV isolates is necessary, which may provide clues about
whether switching to a stable SCV phenotype has conse-
quences for Salmonella pathogenesis. The recent discovery
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that polynucleotide phosphorylase is a global regulator of vir-
ulence and persistence in S. enterica (14) supports the hypoth-
esis that there is a delicate balance between these two pro-
cesses. Additional work is required to confirm whether the
emergence of stable SCV isolates is a consequence of the
interplay between such bacterial regulatory networks and the
host immune defenses.
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